ALX-0761 is a trivalent Nanobody that neutralises both IL-17A and IL-17F and that binds to human serum albumin forin vivohalf-life extension. It is currently in development by Ablynx's partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany. Contact:Dr Edwin Moses,Chairman ...